MedTrace Logo

Teriparatide as a Chondroregenerative Therapy in OA

NCT03072147 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2023-05-12

No results posted yet for this study

Summary

The purpose of this study is to evaluate teriparatide (TP) as a chondroregenerative therapy for human knee osteoarthritis (OA). The central hypothesis to be tested is that TP supports structural modification of the joint and improves biomarker, functional and patient-reported measures of knee OA.

Conditions

Interventions

DRUG

Teriparatide

20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.

DRUG

Placebo

20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.

Sponsors & Collaborators

  • Eli Lilly and Company

    collaborator INDUSTRY

  • University of Rochester

    collaborator OTHER

  • Duke University

    collaborator OTHER

  • Milton S. Hershey Medical Center

    collaborator OTHER

  • Christopher Ritchlin

    lead OTHER

Principal Investigators

  • Michael Zuscik, PhD · University of Rochester

  • Emily Carmody, MD · University of Rochester

  • Christopher Ritchlin, MD · University of Rochester

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2022-09-30
Completion
2022-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03072147 on ClinicalTrials.gov